Merck: experimental I-DXd begins phase 3 trials

(CercleFinance.com) - Daiichi Sankyo and Merck announced today that the first patient has been treated in a Phase 3 trial evaluating the efficacy and safety of the investigational ifinatamab deruxtecan (I-DXd) in patients with recurrent small-cell lung cancer (SCLC) compared to chemotherapy treatment of the physician's choice.


Small cell lung cancer is the second most common type of lung cancer, accounting for around 15% of cases. SCLC is aggressive and progresses rapidly to the metastatic stage, with a five-year survival rate of just 3%.

Patients with small cell lung cancer face poor outcomes with currently available treatments, said the Global Head of Oncology Clinical Development at Daiichi Sankyo.

The IDeate-Lung02 trial is an important step in our research to better understand the role of ifinatamab deruxtecan as a potential new drug for patients with certain types of small-cell lung cancer.


Copyright (c) 2024 CercleFinance.com. All rights reserved.